These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26795703)

  • 21. A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation.
    Rogeberg O; Bergsvik D; Phillips LD; van Amsterdam J; Eastwood N; Henderson G; Lynskey M; Measham F; Ponton R; Rolles S; Schlag AK; Taylor P; Nutt D
    Int J Drug Policy; 2018 Jun; 56():144-152. PubMed ID: 29459211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global patterns of domestic cannabis cultivation: sample characteristics and patterns of growing across eleven countries.
    Potter GR; Barratt MJ; Malm A; Bouchard M; Blok T; Christensen AS; Decorte T; Frank VA; Hakkarainen P; Klein A; Lenton S; Perälä J; Werse B; Wouters M
    Int J Drug Policy; 2015 Mar; 26(3):226-37. PubMed ID: 25582281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabis Prevalence and National Drug Policy in 27 Countries: An Analysis of Adolescent Substance Use.
    Kotlaja MM; Carson JV
    Int J Offender Ther Comp Criminol; 2019 May; 63(7):1082-1099. PubMed ID: 30477367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global Health: A Pivotal Moment Of Opportunity And Peril.
    Gostin LO; Friedman EA
    Health Aff (Millwood); 2017 Jan; 36(1):159-165. PubMed ID: 28069859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peer, professional, and public: an analysis of the drugs policy advocacy community in Europe.
    O'Gorman A; Quigley E; Zobel F; Moore K
    Int J Drug Policy; 2014 Sep; 25(5):1001-8. PubMed ID: 24974366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From Toques to Tokes: Two challenges facing nationwide legalization of cannabis in Canada.
    Bear D
    Int J Drug Policy; 2017 Apr; 42():97-101. PubMed ID: 28377052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'We never thought this would be considered drug trafficking': International finance rules, policy space and Uruguay's regulation of recreational cannabis.
    Barry RA
    Glob Public Health; 2023 Jan; 18(1):2283042. PubMed ID: 37970837
    [No Abstract]   [Full Text] [Related]  

  • 28. The global and domestic politics of health policy in emerging nations.
    Gómez EJ; Ruger JP
    J Health Polit Policy Law; 2015 Feb; 40(1):3-11. PubMed ID: 25480856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Addressing the global tragedy of needless pain: rethinking the United Nations single convention on narcotic drugs.
    Taylor AL
    J Law Med Ethics; 2007; 35(4):556-70, 511. PubMed ID: 18076508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The adverse health effects of cannabis use: what are they, and what are their implications for policy?
    Hall W
    Int J Drug Policy; 2009 Nov; 20(6):458-66. PubMed ID: 19362460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attitudes of cannabis growers to regulation of cannabis cultivation under a non-prohibition cannabis model.
    Lenton S; Frank VA; Barratt MJ; Dahl HV; Potter GR
    Int J Drug Policy; 2015 Mar; 26(3):257-66. PubMed ID: 25181993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug Policy and the Public Good: a summary of the book.
    Drugs and Public Policy Group
    Addiction; 2010 Jul; 105(7):1137-45. PubMed ID: 20642498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug Policy Governance in the UK: lessons from changes to and debates concerning the classification of cannabis under the 1971 Misuse of Drugs Act.
    Monaghan M
    Int J Drug Policy; 2014 Sep; 25(5):1025-30. PubMed ID: 24635973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Should I Buy or Should I Grow?" How drug policy institutions and drug market transaction costs shape the decision to self-supply with cannabis in the Netherlands and the Czech Republic.
    Belackova V; Maalsté N; Zabransky T; Grund JP
    Int J Drug Policy; 2015 Mar; 26(3):296-310. PubMed ID: 25655217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-level governance: The way forward for European illicit drug policy?
    Chatwin C
    Int J Drug Policy; 2007 Dec; 18(6):494-502. PubMed ID: 18061875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Making legitimacy: Drug user representation in United Nations drug policy settings.
    Madden A; Lancaster K; Ritter A; Treloar C
    Int J Drug Policy; 2021 Jan; 87():103014. PubMed ID: 33129132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing civil society participation in the national HIV response: the role of UNGASS reporting.
    Peersman G; Ferguson L; Torres MA; Smith S; Gruskin S
    J Acquir Immune Defic Syndr; 2009 Dec; 52 Suppl 2():S97-103. PubMed ID: 19901632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Legalization of drugs--pro and con].
    Marjanović-Cengić S
    Med Arh; 2001; 55(3):157-9. PubMed ID: 11769432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons from conducting trans-national Internet-mediated participatory research with hidden populations of cannabis cultivators.
    Barratt MJ; Potter GR; Wouters M; Wilkins C; Werse B; Perälä J; Pedersen MM; Nguyen H; Malm A; Lenton S; Korf D; Klein A; Heyde J; Hakkarainen P; Frank VA; Decorte T; Bouchard M; Blok T
    Int J Drug Policy; 2015 Mar; 26(3):238-49. PubMed ID: 25576247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medical use of cannabis in Australia: "medical necessity" defences under current Australian law and avenues for reform.
    Martin C
    J Law Med; 2014 Jun; 21(4):875-99. PubMed ID: 25087368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.